{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/addressing-implications-long-term-follow-discontinued-gene-therapy-studies#webpage",
"url": "https://www.fortrea.com/insights/addressing-implications-long-term-follow-discontinued-gene-therapy-studies",
"name": "Addressing the implications for long-term follow-up in discontinued gene therapy studies",
"description": "This Fortrea white paper explores long-term follow-up considerations in discontinued gene therapy studies and the ongoing responsibilities associated with patient monitoring across advanced therapy research programs. The content focuses on long-term follow-up in gene therapy studies, discontinued gene therapy trials, long-term safety assessment, regulatory considerations, and follow-up obligations affecting sponsors and research teams involved in advanced therapies. The white paper highlights challenges related to maintaining long-term patient monitoring, addressing regulatory expectations, supporting patient communication, and managing follow-up responsibilities after discontinuation of gene therapy studies. Fortrea discusses considerations affecting long-term safety oversight, continued patient follow-up planning, regulatory compliance, and risk management associated with discontinued advanced therapy programs. By integrating regulatory and patient follow-up considerations with long-term safety assessment strategies, the white paper provides insights into managing long-term follow-up obligations in discontinued gene therapy studies and advanced therapy research environments"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Addressing the implications for long-term follow-up in discontinued gene therapy studies",
"item": "https://www.fortrea.com/insights/addressing-implications-long-term-follow-discontinued-gene-therapy-studies"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/addressing-implications-long-term-follow-discontinued-gene-therapy-studies#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/addressing-implications-long-term-follow-discontinued-gene-therapy-studies#webpage"
},
"headline": "Long-Term Follow-Up Considerations in Discontinued Gene Therapy Studies | Fortrea White Paper",
"description": "This Fortrea white paper explores long-term follow-up considerations in discontinued gene therapy studies and the ongoing responsibilities associated with patient monitoring across advanced therapy research programs. The content focuses on long-term follow-up in gene therapy studies, discontinued gene therapy trials, long-term safety assessment, regulatory considerations, and follow-up obligations affecting sponsors and research teams involved in advanced therapies. The white paper highlights challenges related to maintaining long-term patient monitoring, addressing regulatory expectations, supporting patient communication, and managing follow-up responsibilities after discontinuation of gene therapy studies. Fortrea discusses considerations affecting long-term safety oversight, continued patient follow-up planning, regulatory compliance, and risk management associated with discontinued advanced therapy programs. By integrating regulatory and patient follow-up considerations with long-term safety assessment strategies, the white paper provides insights into managing long-term follow-up obligations in discontinued gene therapy studies and advanced therapy research environments",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-04/long-term-follow-up-%20in-discontinued-gene-therapy-studies-1.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-11",
"dateModified": "2025-02-11",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-04/addressing-the-implications-for-long-term-follow-up-%20in-discontinued-gene-therapy-studies_0.pdf",
"encodingFormat": "application/pdf"
}
}
]
}